Science 37, a company focused on “site-less” clinical trials, has entered into a strategic collaboration with global pharmaceutical company UCB regarding the clinical trial experience.
With the use of Science 37’s decentralized approach, participation in UCB studies will result in data that will be more representative of the real-life experience of patients, the companies say. Not only will this approach provide more diverse and relevant data related to the development of new treatments for conditions, but product development timelines also have the potential of being shortened, allowing for certain treatments to hit the market faster. Initial studies in this partnership will be focused in the areas of neurology and immunology.
“We created Science 37 to uniquely combine telemedicine technology, decentralized physician networks, and in-house experienced clinical study staff to take on new and exciting research studies,” says Noah Craft, MD, PhD, and co-founder and CEO of Science 37, in a release. “We are thrilled to join forces and collaborate with UCB for an even better, more realistic patient experience moving forward.”
Science’s 37’s proprietary, cloud-based mobile research platform, the Network Oriented Research Assistant (NORA), enables end-to-end remote clinical trials and adheres to the highest industry quality and regulatory standards. Unlike other mobile health technology companies in the space, Science 37’s Metasite or “site-less” model helps researchers engage directly with trial participants through every stage of planning, from screening and recruitment to data lock. This direct connection online allows for greater retention of patients, increased diversity across trials, and significantly faster recruitment, the company say.
Iris Loew-Friedrich, MD, PhD, executive vice president, and chief medical officer, UCB, says, “UCB’s patient value strategy aims to deliver unique outcomes and the best experience to as many patients as possible. Science 37’s decentralized clinical trial approach combines technologies that can fundamentally change the way clinical trials are run. With this collaboration, we see an opportunity to not only provide a better patient experience but also to innovate and accelerate our clinical studies in a patient-focused way with the aim to bring new solutions to patients faster.”
